169 related items for PubMed ID: 3875277
1. Growth and pubertal development in patients with congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency.
Hochberg Z, Schechter J, Benderly A, Leiberman E, Rosler A.
Am J Dis Child; 1985 Aug; 139(8):771-6. PubMed ID: 3875277
[Abstract] [Full Text] [Related]
2. [Congenital virilizing adrenal hyperplasia due to 11 beta-hydroxylase deficiency. Study of eleven cases (author's transl)].
Dunand A, Roger M, Chaussain JL, Nocton F, Job JC.
Sem Hop; 1985 Aug; 57(33-36):1392-7. PubMed ID: 6270798
[Abstract] [Full Text] [Related]
3. [Medroxyprogesterone acetate. Contributive treatment in congenital adrenal hyperplasia caused by 21-hydroxylase deficiency in children].
La Selve H, Sempé M, Morel Y, Forest MG, de Peretti E, David M.
Arch Fr Pediatr; 1985 Aug; 42(7):511-6. PubMed ID: 2935112
[Abstract] [Full Text] [Related]
4. Growth patterns and outcomes in congenital adrenal hyperplasia; effect of chronic treatment regimens.
Rasat R, Espiner EA, Abbott GD.
N Z Med J; 1995 Aug 11; 108(1005):311-4. PubMed ID: 7644165
[Abstract] [Full Text] [Related]
5. Reduced final height outcome in congenital adrenal hyperplasia under prednisone treatment: deceleration of growth velocity during puberty.
Bonfig W, Bechtold S, Schmidt H, Knorr D, Schwarz HP.
J Clin Endocrinol Metab; 2007 May 11; 92(5):1635-9. PubMed ID: 17299071
[Abstract] [Full Text] [Related]
6. LHRH analog treatment of central precocious puberty complicating congenital adrenal hyperplasia.
Pescovitz OH, Cassorla F, Comite F, Loriaux DL, Cutler GB.
Ann N Y Acad Sci; 1985 May 11; 458():174-81. PubMed ID: 3911847
[No Abstract] [Full Text] [Related]
7. [Case of salt-losing congenital adrenal hyperplasia due to 21-hydroxylase deficiency and a short stature caused by early closure of epiphyseal lines in spite of steroid replacement therapy].
Kondo T, Ueda K, Saito H, Horiuchi Y.
Horumon To Rinsho; 1983 Jul 11; 31(7):637-43. PubMed ID: 6605823
[No Abstract] [Full Text] [Related]
8. Early growth, pubertal development, body mass index and final height of patients with congenital adrenal hyperplasia: factors influencing the outcome.
Manoli I, Kanaka-Gantenbein Ch, Voutetakis A, Maniati-Christidi M, Dacou-Voutetakis C.
Clin Endocrinol (Oxf); 2002 Nov 11; 57(5):669-76. PubMed ID: 12390343
[Abstract] [Full Text] [Related]
9. [Puberty and growth development in patients with a 21-hydroxylase defect].
Börger D, Willig RP.
Monatsschr Kinderheilkd; 1985 Nov 11; 133(11):828-33. PubMed ID: 2934617
[Abstract] [Full Text] [Related]
10. Glucocorticoid treatment of girls with congenital adrenal hyperplasia: effects on height, sexual maturation, and fertility.
Klingensmith GJ, Garcia SC, Jones HW, Migeon CJ, Blizzard RM.
J Pediatr; 1977 Jun 11; 90(6):996-1004. PubMed ID: 870661
[Abstract] [Full Text] [Related]
11. Hydrocortisone dosing during puberty in patients with classical congenital adrenal hyperplasia: an evidence-based recommendation.
Bonfig W, Pozza SB, Schmidt H, Pagel P, Knorr D, Schwarz HP.
J Clin Endocrinol Metab; 2009 Oct 11; 94(10):3882-8. PubMed ID: 19622620
[Abstract] [Full Text] [Related]
12. Non-classical 21-hydroxylase deficiency in infancy and childhood: the effect of time of initiation of therapy on puberty and final height.
Weintrob N, Dickerman Z, Sprecher E, Galatzer A, Pertzelan A.
Eur J Endocrinol; 1997 Feb 11; 136(2):188-95. PubMed ID: 9116914
[Abstract] [Full Text] [Related]
13. [Congenital virilizing adrenal hyperplasia due to 11 -beta-hydroxylase deficiency. Study of 11 cases (author's transl)].
Dunand A, Roger M, Chaussain JL, Nocton F, Job JC.
Ann Pediatr (Paris); 1981 Mar 11; 28(3):179-84. PubMed ID: 7224566
[No Abstract] [Full Text] [Related]
14. Serum 17-hydroxypregnenolone and 17-hydroxypregnenolone sulfate concentrations in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
Shimozawa K, Saisho S, Yata J, Kambegawa A.
Endocrinol Jpn; 1988 Feb 11; 35(1):11-8. PubMed ID: 3260857
[Abstract] [Full Text] [Related]
15. True precocious puberty complicating congenital adrenal hyperplasia: treatment with a luteinizing hormone-releasing hormone analog.
Pescovitz OH, Comite F, Cassorla F, Dwyer AJ, Poth MA, Sperling MA, Hench K, McNemar A, Skerda M, Loriaux DL.
J Clin Endocrinol Metab; 1984 May 11; 58(5):857-61. PubMed ID: 6368580
[Abstract] [Full Text] [Related]
16. Growth and final height in classical and nonclassical 21-hydroxylase deficiency.
New MI, Gertner JM, Speiser PW, del Balzo P.
Acta Paediatr Jpn; 1988 May 11; 30 Suppl():79-88. PubMed ID: 3146882
[No Abstract] [Full Text] [Related]
17. Growth pattern during the first 36 months of life in congenital adrenal hyperplasia (21-hydroxylase deficiency).
Gasparini N, Di Maio S, Salerno M, Argenziano A, Franzese A, Tenore A.
Horm Res; 1997 May 11; 47(1):17-22. PubMed ID: 9010713
[Abstract] [Full Text] [Related]
18. Extraadrenal steroid 21-hydroxylase activity in a woman with congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency.
Winkel CA, Casey ML, Worley RJ, Madden JD, MacDonald PC.
J Clin Endocrinol Metab; 1983 Jan 11; 56(1):104-7. PubMed ID: 6600168
[Abstract] [Full Text] [Related]
19. [Pseudo- and central precocious puberty due to adrenogenital syndrome].
Pouw IS, Drop SL, Ladée-Levy JV, Slijper FM.
Tijdschr Kindergeneeskd; 1986 Jun 11; 54(3):77-83. PubMed ID: 2944246
[Abstract] [Full Text] [Related]
20. Variable efficacy of glucocorticoids in congenital adrenal hyperplasia.
Hansen JW, Loriaux DL.
Pediatrics; 1976 Jun 11; 57(6):942-7. PubMed ID: 934750
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
